Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.2
Industry P/E
24.51
EV/EBITDA
-0.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3
Face value
--
Shares outstanding
1,330,234
CFO
$-84.33 Mln
EBITDA
$-75.11 Mln
Net Profit
$-92.55 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Titan Pharmaceuticals (TTNP)
| 41.4 | 16.4 | 8.2 | -11.4 | -40.2 | -45.8 | -55.0 |
|
BSE Sensex*
| -13.7 | -10.1 | -14.2 | -3.8 | 7.4 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Titan Pharmaceuticals (TTNP)
| -59.9 | -47.6 | -23.5 | -69.0 | -43.5 | -85.5 | -83.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the... treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York. Read more
CEO & Principal Financial Officer
Mr. David Elliot Lazar
CEO & Principal Financial Officer
Mr. David Elliot Lazar
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Titan Pharmaceuticals Inc (TTNP) is $4.61 (NASDAQ) as of 02-Oct-2025 09:30 EDT. Titan Pharmaceuticals Inc (TTNP) has given a return of -40.24% in the last 3 years.
Since, TTM earnings of Titan Pharmaceuticals Inc (TTNP) is negative, P/E ratio is not available.
The P/B ratio of Titan Pharmaceuticals Inc (TTNP) is 2.20 times as on 02-Oct-2025, a 61 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.62
|
1.20
|
|
2023
|
-0.55
|
0.47
|
|
2022
|
-0.57
|
4.25
|
|
2021
|
-0.25
|
0.40
|
|
2020
|
-0.32
|
1.86
|
The 52-week high and low of Titan Pharmaceuticals Inc (TTNP) are Rs 5.76 and Rs 3.03 as of 02-Apr-2026.
Titan Pharmaceuticals Inc (TTNP) has a market capitalisation of $ 6 Mln as on 02-Oct-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Titan Pharmaceuticals Inc (TTNP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.